A5082018603- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Blood disorders and treatments
- CNS Lymphoma Diagnosis and Treatment
- Regional Development and Innovation
- Neutropenia and Cancer Infections
- Cutaneous lymphoproliferative disorders research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Business, Education, Mathematics Research
- Acute Lymphoblastic Leukemia research
- Bacterial Identification and Susceptibility Testing
- Parasites and Host Interactions
- Nutrition and Health in Aging
- Liver Diseases and Immunity
- Asian Culture and Media Studies
- Acne and Rosacea Treatments and Effects
- Cytomegalovirus and herpesvirus research
- Enhanced Recovery After Surgery
- Helminth infection and control
- Lung Cancer Treatments and Mutations
- Parasite Biology and Host Interactions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Medical Imaging Techniques and Applications
University of Florida
2025
Vall d'Hebron Hospital Universitari
2005-2019
Vall d'Hebron Institut de Recerca
2009-2018
Universitat Autònoma de Barcelona
2014
Centre Eugène Marquis
2014
Inserm
2014
École Nationale Supérieure de Chimie de Rennes
2014
Centre National de la Recherche Scientifique
2014
Hospital Madre Teresa
2007
Berger (Canada)
2006
The prognosis of old or immunocompromised patients with refractory relapsing diffuse large-cell lymphoma (DLCL) is very poor as the current standard salvage therapy autologous stem cell transplantation (ASCT) not feasible for most them. New active regimens an acceptable toxicity profile are needed. We aim to report results a phase II trial GEMOX-R regimen in DLCL.A total 32 received 2-wk intervals if every 3 wk planned six eight courses.Median age population was 69 yr. Forty-one percent were...
This phase II, single-arm, multicenter study examined the efficacy and safety of coltuximab ravtansine (an anti-CD19 antibody drug conjugate) in 61 patients with histologically documented (de novo or transformed) relapsed refractory diffuse large B-cell lymphoma who had previously received rituximab-containing immuno-chemotherapy. Patients a median 2.0 (range 0-9) prior treatment regimens for almost half (45.9%) bulky disease (≥1 lesion >5 cm) at trial entry. (55 mg/m2) 4 weekly biweekly...
Summary This prospective multi‐institutional phase II study was designed to assess the efficacy and safety of dose‐adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide doxorubicin) plus rituximab ( DA‐EPOCH‐R ) in untreated patients with poor prognosis large B‐cell lymphomas. Eighty‐one diagnosed diffuse lymphoma DLBCL , n = 68), primary mediastinal 6) follicular Grade 3b 7), an age‐adjusted International Prognostic Index >1, were eligible for analysis. Median age 60 years...
Background: Febrile neutropenia (FN) is associated with disruption of planned chemotherapy and increased management costs. However, the economic impact FN in Spanish clinical practice has not been documented hitherto.Research design methods: A multicenter, retrospective chart review adults breast or lung cancer non-Hodgkin's lymphoma (NHL) who had ≥1 episode during chemotherapy. Resource use, direct costs, effect on were assessed.Main outcome measures: 238 episodes analyzed 194 patients. The...
8506 Background: CoR is an anti-CD19 antibody maytansinoid conjugate. CD19 expressed in the majority of B cell lymphomas. Phase I program showed clinical activity pts with both indolent and aggressive Methods: Pts withCD19+ R/R DLBCL after at least one standard treatment including rituximab not candidate for transplantation were eligible. Primary refractory excluded. Biopsy was required baseline. 55 mg/m² administered weekly 4 weeks then bi-weekly until disease progression or other study...
Some novel valerolactam derivatives of 5(6)-substituted-(1H-benzimidazol-2-yl-amine) were constructed based on the union two structural domains with anthelmintic activity. The tested hybrid compounds 7-9 exhibited greater activity using Nippostrongylus brasiliensis physiology-based in vitro bioassay comparison to commercial benzimidazoles. Moreover, improved physicochemical properties compared domain allowed penetration parasite barriers, concurrently an increased intraparasitary...
Rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 14 days seems to achieve better outcomes than R-CHOP 21 in diffuse large B-cell lymphoma (DLBCL) patients. Currently, the standard regimen is days.This a phase II clinical trial of treatment with 6 cycles R-CHOP-14 pegfilgrastim support 2 populations previously untreated DLBCL patients aged ≥65 years (n = 73) or <65 51) low-risk International Prognostic Index scores (0-2).With median follow-up 63.7 months,...
Abstract Background Cloud‐based image sharing technology allows facilitated of images. has not been well‐studied for acne assessments or treatment preferences, among international evaluators. We evaluated inter‐rater variability grading and recommendations an group dermatologists that assessed photographs. Methods This is a prospective, single visit photographic study to assess agreement photographs shared through integrated mobile device, cloud‐based, HIPAA ‐compliant platform. Inter‐rater...